LINC01374: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01374

NCBI ID: G105378425

LINC01374

Other Name(s): long intergenic non-protein coding RNA 1374 | Long intergenic non-protein coding RNA 1374, transcript variant 1 | TCONS_00018278

LINC01374: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC01374 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is its ability to interact with proteins and other RNAs in the cell. This interaction of LINC01374 with other RNAs has led to its potential involvement as a drug target or biomarker. In this article, we will discuss the potential implications of LINC01374 as a drug target or biomarker, as well as its current research status.

Potential Role as a Drug Target

LINC01374 has been shown to interact with multiple proteins, including the protein encoded by the gene SIRT1. SIRT1 is a NAD+-dependent deoxyribonucleotide reductase, which is involved in various cellular processes, including DNA repair, metabolism, and stress resistance. LINC01374 has been shown to physically interact with SIRT1 by using a unique type of RNA-protein interaction, known as a RNA-protein-RNA interaction.

SIRT1 is a known drug target, and LINC01374 has the potential to interact with it and enhance its effects. This interaction between LINC01374 and SIRT1 may be a promising target for new drugs that are aimed at treating various diseases, including neurodegenerative disorders, cancer, and aging.

Potential Role as a Biomarker

LINC01374 has also been shown to act as a biomarker in various diseases. For example, LINC01374 has been shown to be downregulated in various diseases, including cancer, neurodegenerative disorders, and aging. This downregulation of LINC01374 may indicate a potential therapeutic target or biomarker for these diseases.

Additionally, LINC01374 has been shown to be regulated by various factors, including DNA methylation, RNA binding protein (RBP), and microRNA (miRNA). These factors may play a role in the of LINC01374 and its function as a biomarker or drug target regulation.

Current Research Status

Currently, there is limited research on LINC01374 as a drug target or biomarker. Most of the research that has been conducted on LINC01374 has focused on its function as a protein-protein interaction and its potential role in various diseases.

One study has shown that LINC01374 can interact with SIRT1 and that this interaction may be involved in the regulation of cellular processes, including DNA repair and metabolism. Another study has also shown that LINC01374 can interact with the protein encoded by the gene HDAC1 and that this interaction may be involved in the regulation of various cellular processes, including DNA replication and repair.

Conclusion

In conclusion, LINC01374 is a long intergenic non-protein-coding RNA that has unique features, including its ability to interact with proteins and other RNAs in the cell. The potential role of LINC01374 as a drug target or biomarker is currently being investigated. Further research is needed to fully understand the function of LINC01374 and its potential as a new drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1374

The "LINC01374 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01374 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets